Preston Noon
Director/Board Member at ViTToria Biotherapeutics, Inc.
Preston Noon active positions
| Companies | Position | Start | End |
|---|---|---|---|
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Private Equity Investor | - | - |
ViTToria Biotherapeutics, Inc.
 ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Director/Board Member | - | - |
Career history of Preston Noon
Training of Preston Noon
| University of Connecticut | Masters Business Admin |
Statistics
International
| United States | 4 |
Operational
| Private Equity Investor | 1 |
| Masters Business Admin | 1 |
| Director/Board Member | 1 |
Sectoral
| Finance | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
ViTToria Biotherapeutics, Inc.
ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Preston Noon
- Experience
